#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13994	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2261	615.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1775	1775	T	719	T	681	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13994	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2261	615.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1509	1509	C	812	C	758	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25686	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3692	693.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1733	1733	A	865	A	803	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25686	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3692	693.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2367	2367	C	868	C	779	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25686	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3692	693.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2441	2441	A	791	A	745	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25686	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3692	693.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2993	2993	C	832	C	781	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2016	folP	852	852	99.88	folP.l15.c4.ctg.1	1442	138.6	0	.	p	.	0	E151K	NONSYN	451	453	GAA	700	702	AAA	197;197;202	A;A;A	186;184;189	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2016	folP	852	852	99.88	folP.l15.c4.ctg.1	1442	138.6	1	SNP	p	R228S	1	.	.	682	684	AGC	931	933	AGC	212;213;216	A;G,A;C	196;193,1;194	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5640	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3428	163.7	1	SNP	p	S91F	0	.	.	271	273	TCC	552	554	TCC	217;223;224	T;C;C	197;203;206	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5640	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3428	163.7	1	SNP	p	D95G	0	.	.	283	285	GAC	564	566	GAC	226;225;225	G;A;C	208;205;207	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5640	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3428	163.7	1	SNP	p	D95N	0	.	.	283	285	GAC	564	566	GAC	226;225;225	G;A;C	208;205;207	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1690	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1324	127.1	1	SNP	p	G45D	0	.	.	133	135	GGC	437	439	GGC	198;194;196	G;G;C	186;181;183	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	800	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	962	82.7	0	.	n	.	0	A197.	DEL	197	197	A	550	550	A	180	A	171	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5306	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2978	177.7	1	SNP	p	D86N	0	.	.	256	258	GAC	579	581	GAC	209;210;209	G;A;C	197;196;198	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5306	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2978	177.7	1	SNP	p	S87I	0	.	.	259	261	AGT	582	584	AGT	211;213;216	A;G,T;T	195;198,1;201	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5306	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2978	177.7	1	SNP	p	S87R	0	.	.	259	261	AGT	582	584	AGT	211;213;216	A;G,T;T	195;198,1;201	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5306	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2978	177.7	1	SNP	p	S87W	0	.	.	259	261	AGT	582	584	AGT	211;213;216	A;G,T;T	195;198,1;201	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5306	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2978	177.7	1	SNP	p	S88P	0	.	.	262	264	TCC	585	587	TCC	216;218;220	T;C;C	200;199;205	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4520	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2711	166.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1632	1634	GGC	210;208;206	G;G;C	194;192;189	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1177	1179	GCA	221;221;218	G;C,T;A	204;197,1;201	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1180	1182	ATC	220;221;220	A;T;C	200;205;201	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1192	1194	GTG	213;212;211	G;T;G	193;190;186	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1192	1194	GTG	213;212;211	G;T;G	193;190;186	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1696	1698	ACC	204;202;202	A;C;C	184;188;189	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1750	1752	GCG	212;211;212	G;C;G	186;175;180	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1750	1752	GCG	212;211;212	G;C;G	186;175;180	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1873	1875	GGC	164;164;166	G;G;C	153;155;152	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1882	1884	GGC	169;165;166	G;G;C	153;150;151	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3850	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2334	164.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1900	1902	CTG	148;149;146	C,G;T;G	119,2;112;114	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5554	ponA	2397	2397	100.0	ponA.l6.c17.ctg.1	3311	167.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1648	1650	CCG	185;183;183	C;C;G,A	170;168;159,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2472	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1891	130.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	568	568	C	199	C	185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	482	484	GAA	225;224;222	G;A;A	208;206;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	770	772	GAT	236;237;242	G;A;T	214;215;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	893	895	TCA	249;249;250	T;C;A	222;222;225	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1022	1024	GTC	211;210;211	G;T;C	198;198;199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1034	1036	TCT	217;216;212	T;C;T	206;209;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1352	1354	GCA	207;205;205	G;C;A,G	197;194;195,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	1	SNP	p	G120K	1	.	.	358	360	AAG	728	730	AAG	190;188;191	A;A;G	181;181;180	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	1	SNP	p	A121D	1	.	.	361	363	GAC	731	733	GAC	191;192;192	G;A;C	180;180;180	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2628	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1553	167.9	1	SNP	p	D121N	0	.	.	361	363	GAC	731	733	GAC	191;192;192	G;A;C	180;180;180	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9644	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4844	198.5	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1935	1937	AAT	183;183;182	A;A;T	172;173;170	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	996	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1076	92.0	1	SNP	p	V57M	1	.	.	169	171	ATG	593	595	ATG	214;211;211	A;T;G	198;193;194	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
